Study S001142

Towards a Personalized Precision Medicine in Rare Disease: Tirzepatide (a Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 Receptor Agonist) Monotherapy in Patients With Wolfram Syndrome Type 1

ClinicalTrials.gov record

Registration

Registration: NCT05659368
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: UNKNOWN
Enrollment: 10
Start: 2024-01-01
Primary completion: 2024-10
Lead sponsor: Ospedale San Raffaele
Conditions: Wolfram Syndrome
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2022-003853-70; OTHER_GRANT:PNRR-MR1-2022-12375914

Registered primary outcomes

changing in endogenous insulin production [[Time Frame: month 6±1, month 12±1]]
changing in insulin production [[Time Frame: month 6±1, month 12±1]]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.